

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.90 Billion in July

保瑞公告 7 月自結合併營收新台幣 19 億 0 仟萬元

Taipei, Taiwan, August 10, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenue for July 2026 reached NT\$1.90 billion, up 5.77% year-over-year. Cumulative revenue for the year to date totaled NT\$11,794 million.

台北，台灣，2026 年 8 月 10 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 7 月自結合併營收為新台幣 19 億 0 仟萬元，年對年增加 5.77%，且寫下七月新高，今年累計營收達新台幣 117.94 億。

Bora noted that adjusted quarterly production schedules of major customers at its Zhunan and Canada sites and quality-improvement activity in connection with observations from an FDA audit in 2Q26 on the legacy passive Restricted Access Barrier System (RABS) line affected orders for July. Most of the orders shifted to August and September production schedules with minimal effects on overall Q3 output. With its 12-month order backlog continuing to reach record highs and Rockville facility revenue recognition starting in Q3 with confirmed batch volumes ahead of last year’s run rate, the Company is confident in its third-quarter revenue performance.

保瑞指出，由於暑期竹南廠與加拿大廠主要客戶拉貨時程安排與今年馬里蘭州針劑廠因進行第二季時 FDA 對舊產線被動式限制進入屏障系統 (Passive RABS) 提出改善項目有關的品質專案，小規模降載生產，訂單挪移至 8 至 9 月，但有鑑於未來 12 個月在手訂單屢創新高且新併入的 Rockville 廠區不論是量產或是在手訂單皆較去年暢旺，公司對於第三季業績表現相當有信心。

Pharma Sales’s specialty and brand business of Upsher-Smith continues to see strong demand, and the momentum of generics business remained as strong as the previous 2 months with stabilized pricing in DLS. Sunway Biotech’s Weider Global Nutrition acquisition remained solid and is positioning for stronger momentum heading into the September–October retail peak season.

對全球銷售業務而言，Upsher-Smith 的罕病專科用業績持續攀升，價格回穩後的胃食道逆流學名藥 DLS 延續前月的高市佔表現；子公司晨暉生技新併購的威德表現仍相當穩健，惟在進入九月、十月的零售旺季前將先蹲後跳。

As Bora's large and small molecule CDMO footprint expands in the US, the Company continues to capture durable, high-value demand as customers increasingly prioritize supply resilience and onshore manufacturing. Its growth in specialty and brands and new acquisition by Sunway Biotech shall also allow Bora Group to achieve a more diversified and resilient revenue mix in 2H2026.

隨著保瑞在美國的大小分子 CDMO 布局持續擴展，在客戶日益重視供應韌性與在地產能的趨勢下，集團持續掌握高附加價值的需求並解決製藥客戶們最重要的供應鏈問題。保瑞集團將在 2026 年下半年實

現更多元、更具韌性的營收與獲利結構。

About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com